GE HealthCare announced it received 510(k) clearance from the US Food and Drug Administration (FDA) for its Revolution Vibe CT system, an advanced imaging solution designed specifically for coronary CT angiography (CCTA). The system integrates AI-powered tools and is intended to help clinicians identify potential heart blockages in a non-invasive manner while streamlining workflow.
Advanced Cardiac Imaging Capabilities
The Revolution Vibe is engineered to address difficult cardiac exams, including those involving patients with arrhythmias, heavily calcified coronaries and valves, stents, or bypasses. According to the company, its Unlimited One-Beat Cardiac imaging feature delivers full-heart clarity at a low dose, even in cases without an ECG trace.
The system includes several advanced features: ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and Effortless Cardiac Workflow that help optimize image quality and reduce exam time while enhancing patient comfort.
Clinical Performance Data
In clinical evaluations, the system's Effortless Workflow demonstrated significant efficiency improvements. The technology achieved a 50% reduction in exam time and saved up to five minutes in patient preparation per scan. These efficiencies, driven by automated protocol selection and simplified positioning, also helped to double CCTA capacity. The system minimized reliance on beta blockers and ECG connections while optimizing CCTA exam scheduling.
"Revolution Vibe's FDA clearance comes at the perfect time, with guidelines being adopted clinically for cardiac CT and with positive reimbursement driving procedure growth, this is the time to usher in a new era of cardiac imaging," says Jean-Luc Procaccini, president and CEO, molecular imaging and computed tomography, GE HealthCare. "Designed to help clinicians detect coronary artery disease and help plan valvular heart interventions quickly and confidently—even in complex cases—Revolution Vibe offers a practical, high-performance solution to help improve diagnostic accuracy, reduce exam time, and support better patient outcomes."
First Global Installation
Radiologie du Var – ELSAN in Ollioules, France, is the first healthcare system in the world to install the new technology. The medical imaging provider is known for performing a high volume of cardiovascular imaging in the country.
"With Revolution Vibe in our fleet, we feel better prepared to meet growing demand for cardiac imaging and are proud to offer a fast, noninvasive diagnostic solution to our patients," says Sébastien Saint Germain, director, Radiologie du Var – ELSAN. "In the first couple weeks of use, we're already seeing how its AI-driven workflow and advanced imaging capabilities can help us deliver faster, more confident diagnoses."
Market Impact and Broader Applications
The FDA clearance has driven positive market response, with GE HealthCare shares rising nearly 5.8% since the announcement on September 2. The approval comes at a time when cardiovascular disease remains the leading cause of death globally, with projections of more than 23 million deaths annually by 2030, creating increased demand for cardiac CT angiography tools.
Beyond cardiac imaging, the Revolution Vibe supports general imaging needs and is designed to help facilities manage lifecycle costs with an energy-efficient design, Smart Subscription, and fleet management tools. The system is positioned to help facilities expand their service lines while managing operational expenses.
Revolution Vibe was first introduced with 510k pending status at the American College of Cardiology 2025 meeting in late March 2025, highlighting the company's strategic timing in bringing this technology to market during a period of favorable clinical guidelines and positive reimbursement trends for cardiac CT procedures.
